Factor VIII PEG Conjugation for Hemophilia A Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Factor VIII (FVIII) therapies for hemophilia A have limited half-life and therapeutic effectiveness due to rapid degradation and immunogenicity, necessitating frequent dosing and reduced efficacy.
Innovation Solution
Conjugation of FVIII with a water-soluble polymer, such as polyethylene glycol (PEG), via carbohydrate moieties to extend its half-life and maintain functional activity, using methods like PEGylation where PEG is attached to the FVIII molecule through oxidized carbohydrate moieties, specifically targeting the B domain for conjugation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FVIII is administered as a therapeutic agent for hemophilia A, then it can replace the deficient coagulation factor and improve bleeding symptoms, but it has a short half-life and is rapidly degraded, requiring frequent dosing
Solution Approach 1:
The patent applies composite materials by conjugating FVIII with polyethylene glycol (PEG) to create a hybrid molecule that combines the therapeutic function of FVIII with the stabilizing and half-life-extending properties of PEG. This composite construct protects FVIII from degradation while maintaining its coagulation activity, directly resolving the contradiction between therapeutic effectiveness and short half-life.
Solution Approach 2:
The PEG polymer acts as an intermediary between FVIII and the immune system/degradation pathways. By attaching PEG to FVIII, the patent creates a protective barrier that reduces immunogenicity and protects against proteolytic degradation, thereby extending half-life without compromising the core therapeutic function of FVIII.
2Reliability
If FVIII is administered repeatedly to maintain therapeutic levels, then bleeding symptoms can be managed, but the frequent dosing reduces patient quality of life and increases treatment burden
Solution Approach 1:
The PEG-FVIII composite extends the circulation time of FVIII by protecting it from renal clearance and proteolytic degradation. This allows therapeutic levels to be maintained for longer periods, reducing dosing frequency from multiple times per week to potentially once or twice weekly, thereby reducing treatment burden while maintaining reliability.
Solution Approach 2:
The patent changes the physical-chemical parameters of FVIII by conjugating it with PEG, which alters its hydrodynamic radius, charge distribution, and interaction with plasma proteins. These parameter changes result in reduced renal filtration and decreased susceptibility to degradation, thereby extending half-life and reducing dosing frequency.
3Reliability
If FVIII is purified from plasma to ensure safety and efficacy, then the product is effective for treatment, but the purification process is complex and costly
Solution Approach 1:
The PEG conjugate acts as an intermediary that simplifies purification by providing a distinct hydrodynamic profile and charge characteristics compared to native FVIII. This allows for simpler chromatographic separation steps while maintaining product safety and efficacy, reducing the complexity of the purification process.
4Duration of action of moving object
If FVIII is modified to extend half-life through polymer conjugation, then dosing frequency can be reduced, but the conjugation process must maintain FVIII's functional activity
Solution Approach 1:
The patent applies local quality by selectively conjugating PEG to specific regions of the FVIII molecule (such as the B domain or C2 domain) that are less critical for coagulation function. This localized modification allows half-life extension while preserving the essential functional domains of FVIII, maintaining its ability to bind phospholipids and activate factor X.
Solution Approach 2:
The patent carefully controls the parameters of PEG conjugation, including the degree of substitution, PEG molecular weight, and conjugation chemistry, to optimize the balance between half-life extension and functional activity preservation. By adjusting these parameters, the patent ensures that FVIII retains sufficient coagulation function while achieving extended circulation half-life.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEGylated FVIII construct retains full functional activity with an extended half-life in vivo, reducing dosing frequency and enhancing stability against thrombin inactivation, as demonstrated by increased half-life and maintained biological activity compared to non-conjugated FVIII.
Implementation Method 1
conjugation of FVIII with a water-soluble polymer, such as polyethylene glycol (PEG), via carbohydrate moieties
Implementation Method 2
using methods like PEGylation where PEG is attached to the FVIII molecule through oxidized carbohydrate moieties
Data Source
AI summary
The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.